鉴定 TAE684 是一种强效的 LRRK2 激酶抑制剂。
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
机构信息
MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, United Kingdom.
出版信息
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28.
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is linked to Parkinson's disease and may represent an attractive therapeutic target. Here we report a 2,4-dianilino-5-chloro-pyrimidine, TAE684, a previously reported inhibitor of anaplastic lymphoma kinase (ALK), is also a potent inhibitor of LRRK2 kinase activity (IC(50) of 7.8nM against wild-type LRRK2, 6.1nM against the G2019S mutant). TAE684 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3μM in cells and in mouse spleen and kidney, but not in brain, following oral doses of 10mg/kg.
摘要
富含亮氨酸重复激酶 2（LRRK2）与帕金森病有关，可能是一个有吸引力的治疗靶点。在此，我们报告一种 2,4-二苯胺基-5-氯嘧啶，TAE684，它是一种先前报道的间变性淋巴瘤激酶（ALK）抑制剂，也是 LRRK2 激酶活性的有效抑制剂（对野生型 LRRK2 的 IC50 为 7.8nM，对 G2019S 突变体的 IC50 为 6.1nM）。TAE684 在细胞内和小鼠脾和肾中，以 0.1-0.3μM 的浓度显著抑制野生型 LRRK2 和 G2019S 突变体 Ser910 和 Ser935 的磷酸化，但在脑内没有作用，在口服剂量为 10mg/kg 时也是如此。
相似文献
1
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.鉴定 TAE684 是一种强效的 LRRK2 激酶抑制剂。
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28.
2
GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.GSK2578215A；一种有效的、高度选择性的 2-芳基甲氧基-5-取代-N-芳基苯甲酰胺 LRRK2 激酶抑制剂。
Bioorg Med Chem Lett. 2012 Sep 1;22(17):5625-9. doi: 10.1016/j.bmcl.2012.06.104. Epub 2012 Jul 7.
3
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.帕金森病激酶 LRRK2 的选择性抑制剂的表征。
Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.
4
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.LRRK2 的结合被多种帕金森病相关突变所破坏，并调节其细胞质定位。
Biochem J. 2010 Sep 15;430(3):393-404. doi: 10.1042/BJ20100483.
5
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.LRRK2 激酶活性的抑制导致 Ser(910)/Ser(935)去磷酸化，破坏 14-3-3 结合并改变细胞质定位。
Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784.
6
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.IκB 激酶家族在 Toll 样受体信号转导过程中使帕金森病激酶 LRRK2 磷酸化 Ser935 和 Ser910。
PLoS One. 2012;7(6):e39132. doi: 10.1371/journal.pone.0039132. Epub 2012 Jun 18.
7
Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.采用高通量 TR-FRET 细胞测定法检测 LRRK2 Ser935 磷酸化筛选新型 LRRK2 抑制剂。
PLoS One. 2012;7(8):e43580. doi: 10.1371/journal.pone.0043580. Epub 2012 Aug 28.
8
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.鉴定蛋白磷酸酶 1 作为 LRRK2 磷酸化循环的调节剂。
Biochem J. 2013 Nov 15;456(1):119-28. doi: 10.1042/BJ20121772.
9
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.MLi-2，一种用于探索LRRK2激酶抑制的治疗潜力和安全性的强效、选择性且具有中枢活性的化合物。
J Pharmacol Exp Ther. 2015 Dec;355(3):397-409. doi: 10.1124/jpet.115.227587. Epub 2015 Sep 25.
10
Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.II 型激酶抑制剂对帕金森病相关 LRRK2 突变体 G2019S 表现出一种意想不到的抑制模式。
Biochemistry. 2013 Mar 12;52(10):1725-36. doi: 10.1021/bi3012077. Epub 2013 Mar 1.
引用本文的文献
1
The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease.作为帕金森病新型治疗药物的富含亮氨酸重复激酶2（LRRK2）抑制剂的设计与开发。
Future Med Chem. 2025 Jan;17(2):221-236. doi: 10.1080/17568919.2024.2444875. Epub 2024 Dec 24.
2
Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.帕金森病精准治疗的新视角：通向个性化医疗新突破的多维度证据
Front Aging Neurosci. 2024 Jul 4;16:1417515. doi: 10.3389/fnagi.2024.1417515. eCollection 2024.
3
Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease.用于帕金森病的富含亮氨酸重复激酶2 G2019S突变体抑制剂的多方法计算评估
Mol Divers. 2024 Dec;28(6):4181-4197. doi: 10.1007/s11030-024-10808-w. Epub 2024 Feb 23.
4
Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.帕金森病的精准医学：从遗传风险信号到个性化治疗
Brain Sci. 2022 Sep 28;12(10):1308. doi: 10.3390/brainsci12101308.
5
EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity.EML4-ALK 变体 3 促进有丝分裂错误和纺锤体组装检查点缺陷，导致微管毒剂敏感性增加。
Mol Cancer Res. 2022 Jun 3;20(6):854-866. doi: 10.1158/1541-7786.MCR-21-1010.
6
Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.口服生物可利用的2,4-二芳基氨基嘧啶类似物（DAAP类似物）作为间变性淋巴瘤激酶抑制剂的最新研究进展：发现与临床进展
RSC Adv. 2018 May 4;8(30):16470-16493. doi: 10.1039/c8ra01934g. eCollection 2018 May 3.
7
Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.利用小分子化合物靶向自噬以改善帕金森病的潜在治疗方法。
Acta Pharm Sin B. 2021 Oct;11(10):3015-3034. doi: 10.1016/j.apsb.2021.02.016. Epub 2021 Feb 26.
8
VIP Induces Changes in the F-/G-Actin Ratio of Schlemm's Canal Endothelium via LRRK2 Transcriptional Regulation.VIP 通过 LRRK2 转录调控诱导小梁网内皮细胞 F-/G-actin 比值的变化。
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):45. doi: 10.1167/iovs.61.6.45.
9
Vitamin B modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection.维生素 B 通过别构调节调节帕金森病 LRRK2 激酶活性并发挥神经保护作用。
Cell Res. 2019 Apr;29(4):313-329. doi: 10.1038/s41422-019-0153-8. Epub 2019 Mar 11.
10
Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).睾丸特异性丝氨酸/苏氨酸激酶2（TSSK2）的强效嘧啶和吡咯并嘧啶抑制剂
ChemMedChem. 2017 Nov 22;12(22):1857-1865. doi: 10.1002/cmdc.201700503. Epub 2017 Oct 20.
本文引用的文献
1
Comprehensive analysis of kinase inhibitor selectivity.激酶抑制剂选择性的综合分析。
Nat Biotechnol. 2011 Oct 30;29(11):1046-51. doi: 10.1038/nbt.1990.
2
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.基于化学生物学蛋白质组学的设计，开发出强效的 LRRK2 选择性先导化合物，可减轻人神经元中与帕金森病相关的毒性。
ACS Chem Biol. 2011 Oct 21;6(10):1021-8. doi: 10.1021/cb2002413. Epub 2011 Aug 10.
3
Role of LRRK2 kinase dysfunction in Parkinson disease.LRRK2 激酶功能障碍在帕金森病中的作用。
Expert Rev Mol Med. 2011 Jun 13;13:e20. doi: 10.1017/S146239941100192X.
4
On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.通往富含亮氨酸重复序列激酶2信号传导之路：来自细胞和体内研究的证据。
Neurosignals. 2011;19(1):1-15. doi: 10.1159/000324488. Epub 2011 Mar 23.
5
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.帕金森病激酶 LRRK2 的选择性抑制剂的表征。
Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.
6
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.ALK 激酶与 ATP 竞争抑制剂复合物的晶体结构。
Biochemistry. 2010 Aug 17;49(32):6813-25. doi: 10.1021/bi1005514.
7
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.LRRK2 激酶活性的抑制导致 Ser(910)/Ser(935)去磷酸化，破坏 14-3-3 结合并改变细胞质定位。
Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784.
8
LRRK2 and Parkinson disease.富亮氨酸重复激酶2与帕金森病
Arch Neurol. 2010 May;67(5):542-7. doi: 10.1001/archneurol.2010.79.
9
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.帕金森病中发生突变的蛋白激酶LRRK2的底物特异性与抑制剂
Biochem J. 2009 Oct 23;424(1):47-60. doi: 10.1042/BJ20091035.
10
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.富含亮氨酸重复激酶 2 突变与帕金森病：三个问题。
ASN Neuro. 2009 Apr 14;1(1):e00002. doi: 10.1042/AN20090007.
Zotero 插件